Aclarion (ACON) news
Recent news
Aclarion anticipates having initial internal data readout & expected public disclosure of early interim results in Q4
Aclarion, Inc. (Nasdaq: ACON, ACONW) is preparing for key clinical milestones in 2026, with an initial internal data readout of its 300-patient CLARITY trial expected in the third quarter and public disclosure of early interim results anticipated in the fourth quarter. The CLARITY trial is a…
AInvest Wire · Aug 20, 2026Aclarion rejects Echo Lake Capital’s unsolicited acquisition proposal
AInvest Wire · Jun 8, 2026Aclarion board says Echo Lake proposal significantly undervalues company
AInvest Wire · Jun 8, 2026Ascendiant Capital Maintains Buy on Aclarion, Lowers Price Target to $1.5
Ascendiant Capital Maintains Buy on Aclarion, Lowers Price Target to $1.5 Ascendiant Capital, a renowned financial institution known for its expertise in Finance and Economics, recently initiated coverage on Aclarion, Inc. (Nasdaq: ACON) with a Buy recommendation [1]. This decision comes amidst a…
AInvest Wire · Aug 26, 2024Aclarion slides 13% after filing prospectus related to offering and resale of up to 2.5M shares
Aclarion slides 13% after filing prospectus related to offering and resale of up to 2.5M shares Aclarion, Inc. filed a prospectus related to the offering and resale of up to 2.5 million shares, resulting in a 13% drop in its stock price [1]. The Form S-1 filed with the Securities and Exchange…
AInvest Wire · Jan 23, 2024Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.